Comparison of the Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema Using OCTA
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms REBEL
- 15 Feb 2023 Status changed from recruiting to discontinued due to Insufficient recruitment.
- 26 Nov 2021 Status changed from not yet recruiting to recruiting.
- 13 Aug 2021 New trial record